BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1369@pharmaconomics
DTSTAMP:20260707T034741Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:PHVS PDUFA — deucrictibant
DESCRIPTION:The FDA's approval decision on deucrictibant for hereditary angioedema (HAE) is due Jun 30\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1830487/000119312526219372/phvs-ex99_2.htm\n\nTrack it: https://www.pharmaconomics.com/e/1369
URL:https://www.pharmaconomics.com/e/1369
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PHVS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR